Regeneron Pharmaceuticals Inc. (REGN) exhibits 41.0% gross margins and 9.4% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 20.2x enterprise multiple and 7.4% implied options volatility.
Sustained 41.0% gross profitability converts into 24.9% operating margin and 9.4% ROIC, outpacing sector cost of capital.
ROIC: 9.4% // GM: 41.0%YoY revenue trajectory of +1.0% paired with 5.14% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +1.0% // FCF YLD: 5.14%Altman Z-Score of 7.72 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 7.72 // F-SCORE: 8/9Trading at 18.7x trailing P/E (17.4x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 18.7x // EV/EBITDA: 20.2xOptions market prices a ±7.4% implied move with a 0.84 put/call ratio around $802.00 max pain.
IMPL MOVE: ±7.4% // P/C: 0.84Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 31.4% net margins.
NET MARGIN: 31.4% // D/E: 0.06x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for REGN & activate live FRED threshold breach alerts.